Our Mission

"Pioneer the innovation, development, and commercialization of biomarkers to accurately and quickly diagnose traumatic brain injuries and other neurologic conditions."

Our Company

Banyan Biomarkers, Inc. is creating the first blood test to diagnose traumatic brain injury (TBI). Currently, there is no objective test that exists to detect the presence and severity of brain trauma. Banyan Biomarkers' research has identified unique and proprietary biomarkers present in the patient's blood following injury to the brain. The detection and quantification of these biomarkers may provide early indications of brain trauma essential for earlier intervention and management.

For more information about Banyan Biomarkers, download our Company Fact Sheet PDF

Our Expertise

There are over 70 peer-reviewed publications specific to the company’s assays for the detection of neural injury. These same biomarkers may have the ability to distinguish between stroke and stroke mimics and also provide relative updates on the condition of patients in the neuro-ICU.

Our Technology

Learn more about Banyan Biomarkers Technology

MEET Our Team

  • Henry L. Nordhoff

    Chairman and CEO
  • Jackson Streeter, M.D.

    Chief Medical Officer
  • Steven P. Richieri

    Chief Operating Officer
  • Ronald Hayes, Ph.D.

    Founder, Chief Science Officer
  • Julie Pashkowsky

    VP of Finance
  • Tony Grover

    VP of Business Development
Learn More about Careers at Banyan Biomarkers